A rare case report of linezolid induced thrombocytopenia
Introduction: Oxazolidinone like linezolid are widely used antibiotics because of the growing prevalence of resistant gram-positive infections. Because of its unique mode of action by inhibiting protein synthesis, it is widely effective against various resistant strains like penicillin-resistant and vancomycin-resistant strains of various gram-positive bacteria. It is widely used in the treatment of skin and soft tissue infection including MRSA and MSSA, also used in community-acquired pneumonia, and the combination is used in extensively drug-resistant tuberculosis. The most common side effect of linezolid includes gastrointestinal disturbances like nausea and vomiting. Serious adverse effects include Myelosuppression including thrombocytopenia, anemia, pancytopenia, and leukopenia. Peripheral neuropathy, optic neuritis, and lactic acidosis are also reported.
Case Presentation: Here we report a case of progressive but reversible thrombocytopenia in 75 years old male patient after receiving linezolid therapy for severe sepsis with multi-organ dysfunction with AKI on CKD with hepatic encephalopathy, severe hyponatremia with aspiration pneumonia. On the 9th day of linezolid, therapy thrombocytopenia was noted and immediately linezolid was stopped. After the 12th day, his platelet count went up which might be suggestive of linezolid induced thrombocytopenia.
Conclusion: Physicians should be more vigilant in monitoring complete blood count, especially in elderly patients who are receiving linezolid for more than two weeks. They should also make a risk assessment based on creatinine clearance, baseline platelet count, immunosuppression therapy, baseline hemoglobin, and prior/present antibiotics therapy so that adverse reactions can be prevented.
Bernstein, W. B., Trotta, R. F., Rector, J. T., Tjaden, J. A., & Barile, A. J. (2003). Mechanisms for linezolid-induced anemia and thrombocytopenia. Annals of Pharmacotherapy, 37(4), 517-520.
Choi, G. W., Lee, J. Y., Chang, M. J., Kim, Y. K., Cho, Y., Yu, Y. M., & Lee, E. (2019). Risk factors for linezolid‐induced thrombocytopenia in patients without haemato‐oncologic diseases. Basic & Clinical Pharmacology & Toxicology, 124(2), 228-234.
Cossu, A. P., Musu, M., Mura, P., De Giudici, L. M., & Finco, G. (2014). Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature. European journal of clinical pharmacology, 70(1), 23-28.
French, G. (2003). Safety and tolerability of linezolid. Journal of Antimicrobial Chemotherapy, 51(suppl_2), ii45-ii53.
Halpern, M. (2002). Linezolid-induced pancytopenia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 35(3), 347-348.
Han, X., Wang, J., Zan, X., Peng, L., & Nie, X. (2021). Risk factors for linezolid-induced thrombocytopenia in adult inpatients. International Journal of Clinical Pharmacy, 43(6), 1-9.
Manfredi, R. (2006). Update on the appropriate use of linezolid in clinical practice. Therapeutics and clinical risk management, 2(4), 455.
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., ... & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics, 30(2), 239-245.
Sakka, S. G. (2009). Severe thrombocytopenia in an elderly patient: case report. Reactions, 1257, 20.
Tsuji, Y., Holford, N. H., Kasai, H., Ogami, C., Heo, Y. A., Higashi, Y., & Yamamoto, Y. (2017). Population pharmacokinetics and pharmacodynamics of linezolid‐induced thrombocytopenia in hospitalized patients. British journal of clinical pharmacology, 83(8), 1758-1772.
Waldrep, T. W., & Skiest, D. J. (2002). Linezolid‐induced anemia and thrombocytopenia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 22(1), 109-112.
Copyright (c) 2022 Ashish Karn, Mausam Jain, Bhavya Modi, Riki Patel
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.